|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
UA71971C2
(en)
|
1999-06-04 |
2005-01-17 |
Agoron Pharmaceuticals Inc |
Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
ES2295035T3
(es)
|
1999-07-09 |
2008-04-16 |
Glaxo Group Limited |
Anilinoquinazolinas como inhibidores de proteina tirosina quinasa.
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
EP1274706A1
(en)
|
2000-04-18 |
2003-01-15 |
Agouron Pharmaceuticals, Inc. |
Pyrazoles for inhibiting protein kinases
|
|
NZ569856A
(en)
|
2001-01-05 |
2010-03-26 |
Pfizer |
Antibodies to insulin-like growth factor 1 receptor
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
AU2002351183B2
(en)
*
|
2001-12-06 |
2008-05-08 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
|
DE60232994D1
(de)
*
|
2001-12-06 |
2009-08-27 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
|
US20030180924A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Desimone Robert W. |
Formulation of certain pyrazolo [3,4,-d] pyrimidines as kinase modulators
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
BR0317548A
(pt)
|
2002-12-19 |
2005-11-22 |
Pfizer |
Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
|
|
PL379330A1
(pl)
|
2002-12-20 |
2006-08-21 |
Pfizer Products Inc. |
Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
|
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
|
DE602004017479D1
(de)
|
2003-08-29 |
2008-12-11 |
Pfizer |
Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
RS51362B
(en)
|
2004-08-26 |
2011-02-28 |
Pfizer Inc. |
ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
|
|
ATE501148T1
(de)
*
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
BRPI0609655A2
(pt)
|
2005-03-31 |
2010-03-16 |
Agensys Inc |
anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
|
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
|
JP5357763B2
(ja)
|
2006-11-06 |
2013-12-04 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
|
|
DK2188313T3
(en)
|
2007-08-21 |
2017-12-11 |
Amgen Inc |
HUMAN C-FMS ANTI-BINDING PROTEINS
|
|
ES2424745T3
(es)
|
2007-09-07 |
2013-10-08 |
Agensys, Inc. |
Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
|
EP2962566A1
(en)
|
2008-10-31 |
2016-01-06 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
WO2010090764A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
|
SG174378A1
(en)
|
2009-03-20 |
2011-10-28 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
UA110324C2
(xx)
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Інгібуючі jak сполуки на основі піразолопіримідину
|
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック， インコーポレイテッド |
樹状突起棘の密度を促す方法
|
|
CA2780875A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
EP2523957A1
(en)
|
2010-01-12 |
2012-11-21 |
F. Hoffmann-La Roche AG |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
EP3150610B1
(en)
|
2010-02-12 |
2019-07-31 |
Pfizer Inc |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
|
DK2536748T3
(da)
|
2010-02-18 |
2014-10-13 |
Genentech Inc |
Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
|
|
CN102869359A
(zh)
|
2010-03-17 |
2013-01-09 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶和嘌呤化合物、组合物和使用方法
|
|
CA2793892A1
(en)
|
2010-04-16 |
2011-10-20 |
Elizabeth Punnoose |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
|
ES2695899T3
(es)
|
2010-06-16 |
2019-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Anticuerpos contra endoplasmina y su uso
|
|
EP2612151B1
(en)
|
2010-08-31 |
2017-08-09 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
TW201217387A
(en)
|
2010-09-15 |
2012-05-01 |
Hoffmann La Roche |
Azabenzothiazole compounds, compositions and methods of use
|
|
CN103313987A
(zh)
*
|
2010-11-19 |
2013-09-18 |
弗·哈夫曼-拉罗切有限公司 |
吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
JP6105578B2
(ja)
|
2011-07-21 |
2017-03-29 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
複素環式プロテインキナーゼ阻害剤
|
|
RU2014105624A
(ru)
|
2011-08-12 |
2015-09-20 |
Ф. Хоффманн-Ля Рош Аг |
Соединения индазола, способ их применения и фармацевтическая композиция
|
|
WO2013025853A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
WO2013033380A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
|
CN103827115A
(zh)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶化合物、组合物和使用方法
|
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック， インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
|
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
|
MX2014005570A
(es)
|
2011-11-08 |
2014-05-30 |
Pfizer |
El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
|
|
CN104271761B
(zh)
|
2011-11-30 |
2017-03-15 |
霍夫曼-拉罗奇有限公司 |
癌症中的erbb3突变
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
Ｐｋｍ２調節因子およびそれらの使用方法
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
CA2941010A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
KR20150130491A
(ko)
|
2013-03-13 |
2015-11-23 |
제넨테크, 인크. |
피라졸로 화합물 및 그것의 용도
|
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
RU2015138576A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Комбинации соединения ингибитора мек с соединением ингибитором her3/egfr и способы применения
|
|
TR201911151T4
(tr)
|
2013-03-14 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3041474B1
(en)
|
2013-09-05 |
2020-03-18 |
Genentech, Inc. |
Antiproliferative compounds
|
|
EP3044593A4
(en)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
JP6946000B2
(ja)
|
2013-10-04 |
2021-10-06 |
アプトース バイオサイエンシーズ， インコーポレイテッド |
がんの治療用組成物及び方法
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
AU2014364601A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
SI3126394T1
(sl)
|
2014-03-31 |
2020-01-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti OX40 in postopki uporabe
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
SI3145929T1
(sl)
|
2014-05-23 |
2021-10-29 |
Hoffmann La Roche |
5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze
|
|
US10934360B2
(en)
|
2014-07-31 |
2021-03-02 |
The Hong Kong University Of Science And Technology |
Human monoclonal antibodies against EPHA4 and their use
|
|
JP6814730B2
(ja)
|
2014-09-05 |
2021-01-20 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
CA2966507A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
US20160161485A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
MX2017005929A
(es)
|
2014-11-06 |
2017-11-20 |
Genentech Inc |
Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
JP6639497B2
(ja)
|
2014-11-10 |
2020-02-05 |
ジェネンテック， インコーポレイテッド |
ブロモドメインインヒビターおよびその使用
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
BR112017010198A2
(pt)
|
2014-11-17 |
2017-12-26 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
|
|
CN107531690B
(zh)
|
2014-11-27 |
2020-11-06 |
基因泰克公司 |
用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
|
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
|
CN107109491A
(zh)
|
2014-12-23 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
用于治疗和诊断化学疗法抗性癌症的组合物和方法
|
|
EP3699290A1
(en)
|
2014-12-24 |
2020-08-26 |
F. Hoffmann-La Roche AG |
Therapeutic, diagnostic, and prognostic methods for cancer
|
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
|
JP6659703B2
(ja)
|
2015-01-09 |
2020-03-04 |
ジェネンテック， インコーポレイテッド |
ピリダジノン誘導体および癌の処置におけるそれらの使用
|
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
AU2016252609B2
(en)
|
2015-04-20 |
2022-06-30 |
Sumitomo Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
CN107709344B
(zh)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
用于治疗黄病毒科病毒和癌症的核苷类似物
|
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
PT3298021T
(pt)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
|
|
KR20180012753A
(ko)
|
2015-05-29 |
2018-02-06 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
MX2017014740A
(es)
|
2015-06-08 |
2018-08-15 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
|
|
WO2016205320A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
JP7083497B2
(ja)
|
2015-08-03 |
2022-06-13 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
がんの処置のための併用療法
|
|
CA2996233C
(en)
|
2015-08-26 |
2024-01-16 |
Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos Iii (F.S.P. Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
|
TWI747841B
(zh)
|
2015-09-25 |
2021-12-01 |
美商建南德克公司 |
抗ｔｉｇｉｔ抗體及使用方法
|
|
AU2016369528B2
(en)
|
2015-12-16 |
2021-04-22 |
Genentech, Inc. |
Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
|
|
US10596257B2
(en)
|
2016-01-08 |
2020-03-24 |
Hoffmann-La Roche Inc. |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
TWI742054B
(zh)
|
2016-03-08 |
2021-10-11 |
美商健生生物科技公司 |
Ｇｉｔｒ抗體，方法及用途
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
CN109072311A
(zh)
|
2016-04-15 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
|
WO2017214373A1
(en)
|
2016-06-08 |
2017-12-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
|
MX2019007643A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal.
|
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
RU2769696C2
(ru)
|
2017-05-22 |
2022-04-05 |
Ф. Хоффманн-Ля Рош Аг |
Терапевтические соединения и композиции и способы их применения
|
|
JP2020527351A
(ja)
|
2017-07-21 |
2020-09-10 |
ジェネンテック， インコーポレイテッド |
がんの治療法及び診断法
|
|
KR20200037366A
(ko)
|
2017-08-11 |
2020-04-08 |
제넨테크, 인크. |
항-cd8 항체 및 이의 용도
|
|
CA3075046A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
WO2019226514A2
(en)
|
2018-05-21 |
2019-11-28 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2020014091A
(es)
|
2018-06-23 |
2021-05-27 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
|
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
JP2021535169A
(ja)
|
2018-09-03 |
2021-12-16 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
|
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック， インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
|
MX2021003213A
(es)
|
2018-09-21 |
2021-05-12 |
Genentech Inc |
Metodos de diagnostico para cancer de mama triple negativo.
|
|
US20210393632A1
(en)
|
2018-10-04 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
AU2019403486A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020172712A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
|
|
MX2021011289A
(es)
|
2019-03-22 |
2021-11-03 |
Sumitomo Pharma Oncology Inc |
Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
AU2020341458A1
(en)
|
2019-09-04 |
2022-04-21 |
Genentech, Inc. |
CD8 binding agents and uses thereof
|
|
EP4048693A1
(en)
|
2019-09-27 |
2022-08-31 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
JP2022552873A
(ja)
|
2019-10-24 |
2022-12-20 |
アムジエン・インコーポレーテツド |
がんの治療におけるｋｒａｓ ｇ１２ｃ及びｋｒａｓ ｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
|
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
|
US11608346B2
(en)
|
2019-11-04 |
2023-03-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP2022553857A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ｒａｓ阻害剤
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
WO2021092171A1
(en)
|
2019-11-06 |
2021-05-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
|
JP2023501989A
(ja)
|
2019-11-13 |
2023-01-20 |
ジェネンテック， インコーポレイテッド |
治療用化合物および使用方法
|
|
TW202132296A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
|
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
|
EP4096646A1
(en)
|
2020-01-27 |
2022-12-07 |
Genentech, Inc. |
Methods for treatment of cancer with an anti-tigit antagonist antibody
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
CN115916182A
(zh)
|
2020-06-16 |
2023-04-04 |
基因泰克公司 |
用于治疗三阴性乳腺癌的方法和组合物
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CA3196277A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN116406291A
(zh)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
AU2021409816A1
(en)
|
2020-12-22 |
2023-07-06 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
WO2022235864A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
CA3221390A1
(en)
|
2021-05-25 |
2022-12-01 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
US20230202984A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|